SCHEMBL21955490

SCHEMBL21955490

Cc1nc(S(=O)(=O)Nc2cscn2)ccc1NCc1c(F)cccc1CN1CCCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
SCN1A P35498 20/20 1.00
SCN8A Q9UQD0 20/20 1.00
SCN5A Q14524 18/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21783327 0.99 SCN1A (1.00) SCN1ASCN8ASCN5A
SCHEMBL31017713 0.99 SCN1A (1.00) SCN1ASCN8ASCN5A
SCHEMBL21955500 0.94 SCN1A (1.00) SCN1ASCN8ASCN5A
SCHEMBL31017729 0.94 SCN1A (1.00) SCN1ASCN8ASCN5A
Trifluoroacetic Acid SCHEMBL21955454 0.94 SCN1A (0.89) SCN1ASCN8ASCN5A
SCHEMBL21783424 0.91 SCN1A (1.00) SCN1ASCN8ASCN5A
SCHEMBL31017732 0.91 SCN1A (1.00) SCN1ASCN8ASCN5A
SCHEMBL21783409 0.91 SCN1A (1.00) SCN1ASCN8ASCN5A
SCHEMBL21783354 0.90 SCN1A (1.00) SCN1ASCN8ASCN5A
SCHEMBL21783323 0.88 SCN1A (1.00) SCN1ASCN8ASCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112638879-B Heteroaryl substituted sulfonamide compounds and their use as therapeutic agents 泽农医药公司 2024-06-18 CN claimed
US-10981905-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2021-04-20 US claimed
CN-112638879-A Heteroaryl substituted sulfonamide compounds and their use as therapeutic agents 泽农医药公司 2021-04-09 CN claimed
US-20200157089-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2020-05-21 US claimed
CN-112638879-B Heteroaryl substituted sulfonamide compounds and their use as therapeutic agents 泽农医药公司 2024-06-18 CN disclosed
US-11639351-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. 2023-05-02 US disclosed
US-20220348570-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2022-11-03 US disclosed
US-10981905-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2021-04-20 US disclosed
CN-112638879-A Heteroaryl substituted sulfonamide compounds and their use as therapeutic agents 泽农医药公司 2021-04-09 CN disclosed
US-20200157089-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2020-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11639351-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents SCN1A, SCN2A, SCN2B SCN1A 1/4885SCN8A 6/4885SCN5A 7/4885
US-20200157089-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN2A, SCN2B SCN1A 1/4885SCN8A 6/4885SCN5A 7/4885
US-10981905-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents SCN1A, SCN2A, SCN2B SCN1A 1/4885SCN8A 6/4885SCN5A 7/4885
US-20220348570-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN2A, SCN2B SCN1A 1/4885SCN8A 6/4885SCN5A 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.